A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2011
03/24/2011	CA2773985A1 Protein kinase conjugates and inhibitors
03/24/2011	CA2773832A1 Compounds useful against kinetoplastideae parasites
03/24/2011	CA2773597A1 Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
03/24/2011	CA2773555A1 Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
03/24/2011	CA2773552A1 Treatment of neurological conditions
03/24/2011	CA2773521A1 Oral pharmaceutical compositions comprising amine-containing compounds
03/24/2011	CA2773125A1 Compounds having tafia inhibitory activity
03/24/2011	CA2773003A1 Orally disintegrating pharmaceutical dosage form containing aripiprazole
03/24/2011	CA2772689A1 Glycine compound
03/24/2011	CA2772674A1 Alkene oxindole derivatives and their uses to treat obesity, diabetes and hyperlipidemia
03/24/2011	CA2772504A1 (4-phenyl-piperidin-1-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
03/24/2011	CA2772314A1 Pharmaceutical combination for treating tumor
03/24/2011	CA2772275A1 (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
03/24/2011	CA2772105A1 Fused triazole amines as p2x7 modulators
03/24/2011	CA2771988A1 Process for the synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one (rose bengal) and related xanthenes
03/24/2011	CA2771984A1 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
03/24/2011	CA2771710A1 Aryl sulphone derivatives as calcium channel blockers
03/24/2011	CA2771679A1 4-alkoxy-n- (2-hydroxycarbamoyl-2-piperidinyl-ethyl) -benzamide compounds as selective tace-inhibitors for the treatment of inflammatory diseases
03/24/2011	CA2771612A1 Selective calcium channel modulators
03/24/2011	CA2771168A1 N-[2-hydroxycarbamoyl-2-(piperazinyl)ethyl]benzamide compounds, their preparation and their use as tace inhibitors
03/24/2011	CA2770932A1 Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
03/24/2011	CA2768924A1 Heterocyclic antiviral compounds
03/23/2011	EP2299272A2 N-terminally truncated HER-2/NEU protein as a cancerprognostic indicator
03/23/2011	EP2299266A1 Methods and materials for assessing prostate cancer therapies
03/23/2011	EP2299265A1 Cancer eradication program
03/23/2011	EP2298927A2 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
03/23/2011	EP2298900A1 Compositions and methods for treating intracellular diseases
03/23/2011	EP2298897A1 Regulation of oncogenes by microRNAs
03/23/2011	EP2298803A2 Human G-protein coupled receptor and ligands thereof
03/23/2011	EP2298783A1 Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
03/23/2011	EP2298780A1 Antitumoral derivatives of Ecteinascidin ET-743
03/23/2011	EP2298779A1 Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes
03/23/2011	EP2298778A1 Imidazothiazole derivative having 4,7-diazaspiroý2.5¨octane ring structure
03/23/2011	EP2298776A1 Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
03/23/2011	EP2298775A1 Diazabicyclic central nervous system active agents
03/23/2011	EP2298773A1 6-Cyclomethyl and 6-alkylmethyl substituted pyrazolopyrimidines
03/23/2011	EP2298772A1 Fused heterocyclic compounds
03/23/2011	EP2298770A1 Heterocyclic compounds as TrkA modulators
03/23/2011	EP2298769A1 Xanthin derivatives, their production and utilisation as medicine
03/23/2011	EP2298767A1 Nitrogenated bicyclic heterocyclic compound
03/23/2011	EP2298766A1 Substituted pyridine derivatives
03/23/2011	EP2298765A1 4-Oxadiazolyl-piperidine compounds and use thereof
03/23/2011	EP2298764A1 4-Oxadiazolyl-piperidine compounds and use thereof
03/23/2011	EP2298763A1 Method for producing 1-biphenylmethylimidazole compound
03/23/2011	EP2298762A2 Heterobicyclic compounds with antibacterial activity
03/23/2011	EP2298761A1 HIV inhibiting pyrimidines derivatives
03/23/2011	EP2298760A1 Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
03/23/2011	EP2298759A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases
03/23/2011	EP2298758A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases
03/23/2011	EP2298757A2 Urea compounds active as vanilloid receptor antagonist for the treatment of pain
03/23/2011	EP2298752A1 Alpha-form or beta-form crystal of acetanilide derivative
03/23/2011	EP2298751A2 Polymorphs of ritonavir
03/23/2011	EP2298750A1 Novel isoxazole derivative
03/23/2011	EP2298748A2 Triazole compounds that modulate HSP90 activity
03/23/2011	EP2298747A1 Triazole derivative or salt thereof
03/23/2011	EP2298746A1 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
03/23/2011	EP2298744A2 Opioid receptor modulators
03/23/2011	EP2298743A1 5-membered heterocycle-based P38 kinase inhibitors
03/23/2011	EP2298742A1 Phenoxy acetic acids as PPAR delta activators
03/23/2011	EP2298738A1 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
03/23/2011	EP2298735A1 Aminocyclohexyl ether compounds and uses thereof
03/23/2011	EP2298734A2 Cyclobutyl amine derivatives
03/23/2011	EP2298733A2 Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
03/23/2011	EP2298732A1 7,9-Substituted tetracycline compounds
03/23/2011	EP2298731A1 Amide compound
03/23/2011	EP2298728A1 Transfection reagents
03/23/2011	EP2298416A2 Sustained-release tramadol formulations with 24-hour clinical efficacy
03/23/2011	EP2298415A1 Micronisation method
03/23/2011	EP2298360A2 Methods and immune modulatory nucleic acid compositions for preventing and treating disease
03/23/2011	EP2298359A1 Nucleic acid capable of controlling degranulation of mast cell
03/23/2011	EP2298357A1 Compositions and methods for regulated protein expression in gut
03/23/2011	EP2298353A1 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
03/23/2011	EP2298351A2 Therapeutic antimicrobial compositions and methods
03/23/2011	EP2298350A2 Composition comprising an inducing agent and an anti-viral agent for the treatment of viral disorders
03/23/2011	EP2298348A1 Antibody binding alpha4Beta7 integrin and its use to treat inflammatory bowel disease
03/23/2011	EP2298334A2 Tweak receptor
03/23/2011	EP2298333A2 Tweak receptor
03/23/2011	EP2298332A1 BAFF, inhibitors thereof and their use in the modulation of the B-cell response
03/23/2011	EP2298326A2 Administration of an anti-endotoxin drug by intravenous infusion
03/23/2011	EP2298325A1 Combinations comprising anti-adhesive and prebiotic carbohydrates
03/23/2011	EP2298324A1 Methods of increasing oral bioavailability of tetracyclines
03/23/2011	EP2298323A2 Substituted tetracycline compounds
03/23/2011	EP2298322A2 Substituted tetracycline compounds
03/23/2011	EP2298321A1 Novel pharmaceutical compositions for treating IBD
03/23/2011	EP2298320A1 Use of lanostane and poria extract in treating diabetes
03/23/2011	EP2298319A1 Device and methods for treating paranasal sinus conditions
03/23/2011	EP2298318A1 Device and methods for treating paranasal sinus conditions
03/23/2011	EP2298317A1 Device and methods for treating paranasal sinus conditions
03/23/2011	EP2298316A1 Therapeutic treatment methods
03/23/2011	EP2298315A1 Therapeutic treatment methods
03/23/2011	EP2298314A1 Dosage unit comprising a prostaglandin analog for treating constipation
03/23/2011	EP2298313A1 Pharmaceutical composition for external application containing prochlorperazine
03/23/2011	EP2298312A1 Fluorinated resorufin compounds and their application in detecting hydrogen peroxide
03/23/2011	EP2298311A1 w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
03/23/2011	EP2298310A2 Therapeutic inhibitors of vascular smooth muscle cells
03/23/2011	EP2298309A1 Antitumor agent, kit and method of treating cancer
03/23/2011	EP2298308A2 Integrin-binding small molecules
03/23/2011	EP2298307A1 Pharmaceutical compound containing gestagens and/or oestrogens and 5-methyl-(6S)-tetrahydrofolates
03/23/2011	EP2298306A1 A method of analgesia
03/23/2011	EP2298305A1 4-(N-Phenylamino)-quinazolines/quinolines as inhibitors of tyrosine kinases

1 ... 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 ... 7860